Novartis: Oddo still a buyer, maintains target price

(CercleFinance.com) - Oddo maintains its Outperform rating on Novartis shares, along with its target price of 96 Swiss francs.


The company intends to expand its US footprint from number 10 to 5, Oddo noted after yesterday's analyst meeting in Basel, through recruiting US talent, a higher proportion of US patients in trials, etc.

The key therapeutic areas remain unchanged: cardiovascular, immunology, neuroscience, solid tumours and haematology. Oddo also notes that three products should be watched closely: iptacopan, pelacarsen and remibrutinib.

For the analyst, the combination of the flagship drugs Cosentyx, Entresto, Kisqali, Kesimpta, Zolgensma and Leqvio and the progressive portfolio renewal should enable the group to achieve its objectives.


Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.